Journey Medical Corporation drugs
7 results
Amzeeq (minocycline)
(Minocycline)Journey Medical Corporation
Usage: AMZEEQ is indicated for the topical treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and patients aged 9 years and older. It is not evaluated for infection treatment and should be used as directed to prevent drug resistance.
Emrosi (minocycline hydrochloride extended-release)
(Minocycline Hydrochloride Extended-Release)Journey Medical Corporation
Usage: EMROSI is indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. It is not evaluated for infection treatment or prevention and should be used as indicated to avoid drug-resistant bacteria.
Exelderm (sulconazole nitrate)
(Sulconazole Nitrate)Journey Medical Corporation
Usage: EXELDERM (sulconazole nitrate, USP) CREAM, 1.0% is indicated for treating tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by specific fungi, as well as tinea versicolor. Efficacy against Microsporum canis was studied in a limited number of infections.
Qbrexza (glycopyrronium)
(glycopyrronium)Journey Medical Corporation
Usage: Qbrexza is indicated for the topical treatment of primary axillary hyperhidrosis in adults and pediatric patients aged 9 years and older.
Targadox (doxycycline hyclate)
(doxycycline hyclate)Journey Medical Corporation
Usage: TARGADOX® (doxycycline) is indicated for treating various infections caused by susceptible bacteria, including respiratory, urinary, and certain serious infections like anthrax. It is also used for malaria prophylaxis and as adjunctive therapy for acne and intestinal amebiasis. Use is advised only when bacterial susceptibility is confirmed.
Ximino (minocycline hydrochloride)
(minocycline hydrochloride)Journey Medical Corporation
Usage: Ximino is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 12 and older. It is not effective against non-inflammatory acne and has not been evaluated for infections. Safety beyond 12 weeks of use is not established.
Zilxi (minocycline)
(Minocycline)Journey Medical Corporation
Usage: ZILXI is indicated for treating inflammatory lesions of rosacea in adults. It is not evaluated for infection treatment, and its use should be limited to the specified indication to reduce drug-resistant bacteria and maintain antibacterial effectiveness.